



Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief **>>**

ISSN (Print): 1871-5206

ISSN (Online): 1875-5992

Back

Journal **▼**

Subscribe

Research Article

Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8

Author(s): [Heidy Martínez-Pacheco](#), [Guillermo Ramírez-Galicia](#), [Midalia Vergara-Arias](#), [Jurg Gertsch](#), [Jonathan Manuel Fragoso-Vazquez](#), [David Mendez-Luna](#), [A. L. Abujamra](#), [Cabrera-Perez Laura Cristina](#), [Rosales-Hernandez Martha Cecilia](#), [I Mendoza-Lujambio](#) and [Jose Correa-Basurto*](#)


Volume 17, Issue 7, 2017

Page: [927 - 940]

Pages: 14

DOI: [10.2174/1871520616666161019143219](https://doi.org/10.2174/1871520616666161019143219)

Price: \$65



Abstract

Background: Histone deacetylase 8 (HDAC8) is a plausible target for the development of novel anticancer drugs using a metal-chelating group and hydrophobic moieties as pharmacophores. It is known that valproic acid (administered as its salt, sodium valproate; VPANa+) is an HDAC8 inhibitor characterized by its hydrophobic chains. Nevertheless, VPA is hepatotoxic and VPA analogues might be explored for less hepatotoxic antiproliferative compounds.